| HOME >> MEDICINE >> TECHNOLOGY |
Figure 87: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Type, 2009 – Q1 2011 104
Figure 88: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Geography, 2009 – Q1 2011 105
Figure 89: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Therapy Area, 2009 – Q1 2011 106
Figure 90: Licensing Strategies in Large Pharmaceutical Companies, Bayer, Licensing Deals By Phase, 2009 – Q1 2011 107
Figure 91: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Number of Licensing Deals, 2005 – Q1 2011 108
Figure 92: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Value, 2006–2010 109
Figure 93: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Number of Licensing Deals By Value, 2005 – 2010 110
Figure 94: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Type, 2009 – Q1 2011 111
Figure 95: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Geography, 2009 – Q1 2011 112
Figure 96: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Therapy Area, 2009 – Q1 2011 113
Figure 97: Licensing Strategies in Large Pharmaceutical Companies, AstraZeneca, Licensing Deals By Phase 2009 – Q1 2011 114
Figure 98: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Number of Licensing Deals, 2005 – Q1 2011 115
Figure 99: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Licensing Deals By Value, 2006 – 2010 116
Figure 100: Licensing Strategies in Large Pharmaceutical Companies, Astellas, Number of Licensing Deals By Value, 2005 – Q1 2011 117
Figure 101: Licensing Strategies in Large Pharmaceutical Compa
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |